Altravax, Inc.
5Patents
5Active
5Granted
45Portfolio score
Filing activity: Aug 30, 2007 → Mar 12, 2014 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8715694B2 | Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein | Emerging Cross-Sectional Technologies | 50 | Active |
| US8158131B2 | Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein | Emerging Cross-Sectional Technologies | 4 | Active |
| US9353158B2 | Hepatitis B virus vaccines | Chemistry; Metallurgy | 3 | Active |
| US8168772B2 | Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling | Emerging Cross-Sectional Technologies | 2 | Active |
| US9186397B2 | Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.